

Conghua Xie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/777138/publications.pdf>

Version: 2024-02-01

102
papers

3,539
citations

304743

22
h-index

161849

54
g-index

111
all docs

111
docs citations

111
times ranked

6479
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. <i>JAMA Oncology</i> , 2020, 6, 1108.	7.1	862
2	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , 2020, 25, e936-e945.	3.7	520
3	Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2016, 388, 1883-1892.	13.7	406
4	Fear of disease progression and psychological stress in cancer patients under the outbreak of COVID-19. <i>Psycho-Oncology</i> , 2020, 29, 1395-1398.	2.3	84
5	Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. <i>Cancer</i> , 2020, 126, 4023-4031.	4.1	82
6	Cancer-associated fibroblasts mediated chemoresistance by a FOXO1/TGF β 21 signaling loop in esophageal squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2017, 56, 1150-1163.	2.7	67
7	Treatment and Outcome of a Patient With Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2. <i>Journal of Thoracic Oncology</i> , 2020, 15, e63-e64.	1.1	52
8	Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3273-3282.	1.6	48
9	USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. <i>Nature Communications</i> , 2022, 13, 1700.	12.8	45
10	Deubiquitinase USP9X deubiquitinates β -catenin and promotes high grade glioma cell growth. <i>Oncotarget</i> , 2016, 7, 79515-79525.	1.8	40
11	Knockdown of <i>SIRT1</i> Suppresses Bladder Cancer Cell Proliferation and Migration and Induces Cell Cycle Arrest and Antioxidant Response through FOXO3a-Mediated Pathways. <i>BioMed Research International</i> , 2017, 2017, 1-14.	1.9	38
12	EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data. <i>OncoTargets and Therapy</i> , 2014, 7, 2075.	2.0	37
13	Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. <i>Annals of Oncology</i> , 2019, 30, 637-643.	1.2	37
14	FePt-Cys nanoparticles induce ROS-dependent cell toxicity, and enhance chemo-radiation sensitivity of NSCLC cells in vivo and in vitro. <i>Cancer Letters</i> , 2018, 418, 27-40.	7.2	34
15	Immunomodulation of NK Cells by Ionizing Radiation. <i>Frontiers in Oncology</i> , 2020, 10, 874.	2.8	32
16	Radiation-induced autophagy promotes esophageal squamous cell carcinoma cell survival via the LKB1 pathway. <i>Oncology Reports</i> , 2016, 35, 3559-3565.	2.6	30
17	Concomitant underexpression of TGFBR2 and overexpression of hTERT are associated with poor prognosis in cervical cancer. <i>Scientific Reports</i> , 2017, 7, 41670.	3.3	30
18	Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e044661.	1.9	30

#	ARTICLE	IF	CITATIONS
19	Radiotherapy activates autophagy to increase CD8 ⁺ T cell infiltration by modulating major histocompatibility complex class-I expression in non-small cell lung cancer. <i>Journal of International Medical Research</i> , 2019, 47, 3818-3830.	1.0	29
20	Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors. <i>Cancer Communications</i> , 2020, 40, 374-379.	9.2	29
21	RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma. <i>Cell and Bioscience</i> , 2021, 11, 74.	4.8	27
22	Hollow PtCo alloy nanospheres as a high-Z and oxygen generating nanozyme for radiotherapy enhancement in non-small cell lung cancer. <i>Journal of Materials Chemistry B</i> , 2021, 9, 4643-4653.	5.8	27
23	<p>Recent Progress of Nanoscale Metal-Organic Frameworks in Cancer Theranostics and the Challenges of Their Clinical Application</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 10195-10207.	6.7	26
24	A Six-Gene Signature Predicts Survival of Adenocarcinoma Type of Non-Small-Cell Lung Cancer Patients: A Comprehensive Study Based on Integrated Analysis and Weighted Gene Coexpression Network. <i>BioMed Research International</i> , 2019, 2019, 1-16.	1.9	25
25	Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells. <i>International Journal of Oncology</i> , 2013, 42, 699-711.	3.3	24
26	Downregulation of Ubiquitin-conjugating Enzyme UBE2D3 Promotes Telomere Maintenance and Radioresistance of Eca-109 Human Esophageal Carcinoma Cells. <i>Journal of Cancer</i> , 2016, 7, 1152-1162.	2.5	24
27	Small Nucleolar RNA 71A Promotes Lung Cancer Cell Proliferation, Migration and Invasion via MAPK/ERK Pathway. <i>Journal of Cancer</i> , 2019, 10, 2261-2275.	2.5	24
28	Protective Role of Nuclear Factor-Erythroid 2-Related Factor 2 Against Radiation-Induced Lung Injury and Inflammation. <i>Frontiers in Oncology</i> , 2018, 8, 542.	2.8	23
29	The potential role of borophene as a radiosensitizer in boron neutron capture therapy (BNCT) and particle therapy (PT). <i>Biomaterials Science</i> , 2020, 8, 2778-2785.	5.4	22
30	Suppression of telomere-binding protein TPP1 resulted in telomere dysfunction and enhanced radiation sensitivity in telomerase-negative osteosarcoma cell line. <i>Biochemical and Biophysical Research Communications</i> , 2014, 445, 363-368.	2.1	21
31	Outcomes in Radiotherapy-Treated Patients With Cancer During the COVID-19 Outbreak in Wuhan, China. <i>JAMA Oncology</i> , 2020, 6, 1457.	7.1	21
32	FePt/GO Nanosheets Suppress Proliferation, Enhance Radiosensitization and Induce Autophagy of Human Non-Small Cell Lung Cancer Cells. <i>International Journal of Biological Sciences</i> , 2019, 15, 999-1009.	6.4	20
33	HHLA2 deficiency inhibits non-small cell lung cancer progression and THP-1 macrophage M2 polarization. <i>Cancer Medicine</i> , 2021, 10, 5256-5269.	2.8	19
34	Prognostic Nomogram for Patients with Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy. <i>PLoS ONE</i> , 2015, 10, e0134491.	2.5	19
35	Feasibility of a novel dose fractionation strategy in TMI/TMLI. <i>Radiation Oncology</i> , 2018, 13, 248.	2.7	18
36	Î±7â€nAChR agonist GTSâ€21 reduces radiation-induced lung injury. <i>Oncology Reports</i> , 2018, 40, 2287-2297.	2.6	18

#	ARTICLE	IF	CITATIONS
37	MiR-34b regulates cervical cancer cell proliferation and apoptosis. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 2042-2047.	2.8	18
38	Alert to Potential Contagiousness: A Case of Lung Cancer With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Thoracic Oncology</i> , 2020, 15, e82-e83.	1.1	17
39	β -catenin is regulated by USP9x and mediates resistance to TRAIL-induced apoptosis in breast cancer. <i>Oncology Reports</i> , 2016, 35, 717-724.	2.6	16
40	The effect of the TLR9 ligand CpG-oligodeoxynucleotide on the protective immune response to radiation-induced lung fibrosis in mice. <i>Molecular Immunology</i> , 2016, 80, 33-40.	2.2	16
41	Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer. <i>Cancer Medicine</i> , 2019, 8, 4605-4614.	2.8	16
42	Establishment of the Prognostic Index Reflecting Tumor Immune Microenvironment of Lung Adenocarcinoma Based on Metabolism-Related Genes. <i>Journal of Cancer</i> , 2020, 11, 7101-7115.	2.5	16
43	Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 9581-9594.	2.8	16
44	The prognostic value of tumor mutational burden and immune cell infiltration in esophageal cancer patients with or without radiotherapy. <i>Aging</i> , 2020, 12, 4603-4616.	3.1	16
45	MiR-195 restrains lung adenocarcinoma by regulating CD4+ T cell activation via the CCDC88C/Wnt signaling pathway: a study based on the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and bioinformatic analysis. <i>Annals of Translational Medicine</i> , 2019, 7, 263-263.	1.7	15
46	Prediction of IDH Status Through MRI Features and Enlightened Reflection on the Delineation of Target Volume in Low-Grade Gliomas. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381987716.	1.9	15
47	Value of radiotherapy in addition to esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma: Analysis of surveillance, epidemiology, and end results database. <i>Cancer Medicine</i> , 2019, 8, 21-27.	2.8	15
48	β -PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8 ⁺ T-cell infiltration. <i>Immunotherapy</i> , 2019, 11, 101-118.	2.0	15
49	A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation. <i>Journal of Clinical Oncology</i> , 2017, 35, 8531-8531.	1.6	15
50	PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 1827-1837.	2.4	14
51	LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non-small cell lung cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, e792.	4.0	14
52	Optimal dose limitation strategy for bone marrow sparing in intensity-modulated radiotherapy of cervical cancer. <i>Radiation Oncology</i> , 2019, 14, 118.	2.7	13
53	A prognostic eight-gene expression signature for patients with breast cancer receiving adjuvant chemotherapy. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3923-3934.	2.6	13
54	NEK2 plays an active role in Tumorigenesis and Tumor Microenvironment in Non-Small Cell Lung Cancer. <i>International Journal of Biological Sciences</i> , 2021, 17, 1995-2008.	6.4	13

#	ARTICLE	IF	CITATIONS
55	UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 87-98.	2.3	12
56	Mapping patterns of metastatic lymph nodes for postoperative radiotherapy in thoracic esophageal squamous cell carcinoma: a recommendation for clinical target volume definition. <i>BMC Cancer</i> , 2019, 19, 927.	2.6	12
57	Establishment of the prognostic index of lung squamous cell carcinoma based on immunogenomic landscape analysis. <i>Cancer Cell International</i> , 2020, 20, 330.	4.1	12
58	Immune and stromal scoring system associated with tumor microenvironment and prognosis: a gene-based multi-cancer analysis. <i>Journal of Translational Medicine</i> , 2021, 19, 330.	4.4	12
59	Mutational burden and chromosomal aneuploidy synergistically predict survival from radiotherapy in non-small cell lung cancer. <i>Communications Biology</i> , 2021, 4, 131.	4.4	12
60	Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis. <i>Molecular and Clinical Oncology</i> , 2015, 3, 720-724.	1.0	11
61	Systematic Profiling of Immune Risk Model to Predict Survival and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 576566.	2.3	11
62	The change in peripheral blood monocyte count: A predictor to make the management of chemotherapy-induced neutropenia. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 565.	0.9	11
63	Radiation-induced lung fibrosis in a tumor-bearing mouse model is associated with enhanced Type-2 immunity. <i>Journal of Radiation Research</i> , 2016, 57, 133-141.	1.6	10
64	Establishment of Immune-related Gene Pair Signature to Predict Lung Adenocarcinoma Prognosis. <i>Cell Transplantation</i> , 2020, 29, 096368972097713.	2.5	10
65	<p>Neutrophil"lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas". <i>Cancer Management and Research</i> , 2019, Volume 11, 6003-6009.	1.9	9
66	The Management of Patients With Lung Cancer During the Outbreak of Coronavirus Disease 2019. <i>Journal of Thoracic Oncology</i> , 2020, 15, e106-e107.	1.1	9
67	MFP-FePt-GO Nanocomposites Promote Radiosensitivity of Non-Small Cell Lung Cancer Via Activating Mitochondrial-Mediated Apoptosis and Impairing DNA Damage Repair. <i>International Journal of Biological Sciences</i> , 2020, 16, 2145-2158.	6.4	9
68	Agrin Promotes Non-Small Cell Lung Cancer Progression and Stimulates Regulatory T Cells via Increasing IL-6 Secretion Through PI3K/AKT Pathway. <i>Frontiers in Oncology</i> , 2021, 11, 804418.	2.8	9
69	Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis. <i>Oncology Letters</i> , 2015, 9, 2825-2832.	1.8	8
70	MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer. <i>International Journal of Biological Sciences</i> , 2021, 17, 1671-1681.	6.4	8
71	Expression of human protection of telomere 1 correlates with telomere length and radiosensitivity in the human laryngeal cancer Hep-2 cell line. <i>Oncology Letters</i> , 2015, 10, 1149-1154.	1.8	7
72	Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. <i>Journal of Cancer</i> , 2020, 11, 2060-2067.	2.5	7

#	ARTICLE	IF	CITATIONS
73	Effects of Enteral Nutrition on Patients With Oesophageal Carcinoma Treated With Concurrent Chemoradiotherapy: A Prospective, Multicentre, Randomised, Controlled Study. <i>Frontiers in Oncology</i> , 2022, 12, 839516.	2.8	7
74	Evaluation and improvement the safety of total marrow irradiation with helical tomotherapy using repeat failure mode and effects analysis. <i>Radiation Oncology</i> , 2019, 14, 238.	2.7	6
75	Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2020, 20, 699.	2.6	6
76	Stromal microenvironment promoted infiltration in esophageal adenocarcinoma and squamous cell carcinoma: a multi-cohort gene-based analysis. <i>Scientific Reports</i> , 2020, 10, 18589.	3.3	6
77	BRD4 inhibition promotes TRAIL-induced apoptosis by suppressing the transcriptional activity of NF- κ B in NSCLC. <i>International Journal of Medical Sciences</i> , 2021, 18, 3090-3096.	2.5	6
78	A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 4665-4674.	4.3	6
79	A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1621-1628.	2.5	5
80	Metachronous Brain Metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis. <i>Journal of Cancer</i> , 2020, 11, 7283-7290.	2.5	5
81	Pathologic evolution-related Gene Analysis based on both single-cell and bulk transcriptomics in Colorectal Cancer. <i>Journal of Cancer</i> , 2020, 11, 6861-6873.	2.5	5
82	Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study. <i>Cancer Medicine</i> , 2021, 10, 4282-4290.	2.8	5
83	Effects of MicroRNA-195-5p on Biological Behaviors and Radiosensitivity of Lung Adenocarcinoma Cells via Targeting HOXA10. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-18.	4.0	5
84	GPR87 promotes tumor cell invasion and mediates the immunogenomic landscape of lung adenocarcinoma. <i>Communications Biology</i> , 2022, 5, .	4.4	5
85	Prophylactic cranial irradiation for extensive-stage small cell lung cancer: Analysis based on active brain MRI surveillance. <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 16-21.	1.7	4
86	Enteral nutrition to improve nutritional status, treatment tolerance, and outcomes in patients with esophageal cancer undergoing concurrent chemoradiotherapy (CCRT): Results of a prospective, randomized, controlled, multicenter trial (NCT 02399306).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4033-4033.	1.6	4
87	The characteristic of tumor immune microenvironment in pulmonary carcinosarcoma. <i>Immunotherapy</i> , 2020, 12, 323-331.	2.0	4
88	Systematic Analyses of a Chemokine Family-Based Risk Model Predicting Clinical Outcome and Immunotherapy Response in Lung Adenocarcinoma. <i>Cell Transplantation</i> , 2021, 30, 096368972110550.	2.5	4
89	Risk of COVID-19 in Patients With Cancer”Reply. <i>JAMA Oncology</i> , 2020, 6, 1472.	7.1	3
90	The safety and efficacy of a novel hypo-fractionated total marrow and lymphoid irradiation before allogeneic stem cell transplantation for lymphoma and acute leukemia. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 42-46.	1.7	3

#	ARTICLE	IF	CITATIONS
91	Reply to Colorectal cancer and COVID-19: Do we need to raise awareness and vigilance?. <i>Cancer</i> , 2021, 127, 980-981.	4.1	3
92	Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small-cell lung cancer: a network meta-analysis. <i>Future Oncology</i> , 2022, 18, 1651-1664.	2.4	3
93	SETD2 mediates immunotherapy and radiotherapy efficacy via regulating DNA damage responses and genomic stability in lung adenocarcinoma. <i>Genes and Diseases</i> , 2023, 10, 336-339.	3.4	3
94	Î2-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors. <i>International Journal of Oncology</i> , 2018, 53, 2258-2268.	3.3	2
95	Correction: The potential role of borophene as a radiosensitizer in boron neutron capture therapy (BNCT) and particle therapy (PT). <i>Biomaterials Science</i> , 2021, 9, 2743-2744.	5.4	2
96	Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma. <i>Supportive Care in Cancer</i> , 2022, , 1.	2.2	2
97	Nimotuzumab combined with cisplatin plus fluorouracil chemotherapy in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: A multicentre, open-label, phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6028-6028.	1.6	1
98	Additional Postoperative Radiotherapy Prolonged the Survival of Patients with I-IIA Small Cell Lung Cancer: Analysis of the SEER Database. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	1.3	1
99	Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19. <i>Scientific Reports</i> , 2021, 11, 17381.	3.3	0
100	Effect of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy on nutritional status in locoregionally advanced nasopharyngeal carcinoma patients: A prospective observational study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18002-e18002.	1.6	0
101	Concurrent Chemoradiotherapy with Extended Nodal Irradiation and/or Erlotinib in Locally Advanced Esophageal Squamous Cell Cancer: Long-Term Follow-Up of a Randomized Phase 3 Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
102	Abstract LB549: LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signaling in non-small cell lung cancer. <i>Cancer Research</i> , 2022, 82, LB549-LB549.	0.9	0